Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017

Antiviral Research

Volumn 157, Issue , 2018, Pages 38-46

  Lackenby, Angie ^a   Besselaar, Terry G ^b   Daniels, Rod S ^c   Fry, Alicia ^d   Gregory, Vicki ^c   Gubareva, Larisa V ^d   Huang, Weijuan ^e   Hurt, Aeron C ^f,g   Leang, Sook Kwan ^f   Lee, Raphael T C ^h   Lo, Janice ⁱ   Lollis, Lori ^d   Maurer Stroh, Sebastian ^h,j,k   Odagiri, Takato ^l   Pereyaslov, Dmitriy ^b   Takashita, Emi ^l   Wang, Dayan ^e   Zhang, Wenqing ^b   Meijer, Adam ^m  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e National Institute for Viral Disease Control and Prevention   (China)

^f PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h BIOINFORMATICS INSTITUTE   (Singapore)

ⁱ DEPARTMENT OF HEALTH   (Hong Kong)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k MINISTRY OF HEALTH   (Singapore)

^l NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^m NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

more..

Author keywords

Influenza; Inhibitor; Neuraminidase; Resistance; Surveillance; Susceptibility

Indexed keywords

ANTIVIRUS AGENT; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR; ENZYME INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DISEASE SURVEILLANCE; DRUG MONITORING; DRUG SENSITIVITY; ENZYME INHIBITION; HONG KONG INFLUENZA; HUMAN; IC50; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA VIRUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PRIORITY JOURNAL; SEQUENCE DATABASE; VICTORIA; WORLD HEALTH ORGANIZATION; ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG EFFECT; ENZYMOLOGY; GENETICS; GLOBAL HEALTH; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MISSENSE MUTATION; ORTHOMYXOVIRIDAE; PREVALENCE; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GLOBAL HEALTH; HUMANS; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PREVALENCE; SEQUENCE ANALYSIS, DNA;

EID: 85049474541     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2018.07.001     Document Type: Article

References (37)

1. Bright, R.A., Medina, M.-j., Xu, X., Perez-Oronoz, G., Wallis, T.R., Davis, X.M., Povinelli, L., Cox, N.J., Klimov, A.I., Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. The Lancet 366 (2005), 1175–1181.
2. Byrn, R.A., Jones, S.M., Bennett, H.B., Bral, C., Clark, M.P., Jacobs, M.D., Kwong, A.D., Ledeboer, M.W., Leeman, J.R., McNeil, C.F., Murcko, M.A., Nezami, A., Perola, E., Rijnbrand, R., Saxena, K., Tsai, A.W., Zhou, Y., Charifson, P.S., Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob. Agents Chemother. 59 (2015), 1569–1582.
3. Epstein, C., Experience with favipiravir in phase 3 and implications for future studies. 5th Isirv-AVG Conference; Prevention and Treatment of RVIs: Antivirals, Traditional Therapies and Host-directed Interventions, Shanghai, China, 2017.
4. Fujisaki, S., Imai, M., Takashita, E., Taniwaki, T., Xu, H., Kishida, N., Yokoyama, M., Sato, H., Tashiro, M., Odagiri, T., Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs. J. Infect. Chemother. 19 (2013), 891–895.
5. Gubareva, L.V., Matrosovich, M.N., Brenner, M.K., Bethell, R.C., Webster, R.G., Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 (1998), 1257–1262.
6. Gubareva, L.V., Besselaar, T.G., Daniels, R.S., Fry, A., Gregory, V., Huang, W., Hurt, A.C., Jorquera, P.A., Lackenby, A., Leang, S.K., Lo, J., Pereyaslov, D., Rebelo-de-Andrade, H., Siqueira, M.M., Takashita, E., Odagiri, T., Wang, D., Zhang, W., Meijer, A., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antivir. Res. 146 (2017), 12–20.
7. Gubareva, L.V., Fallows, E., Mishin, V.P., Hodges, E., Brooks, A., Barnes, J., Fry, A.M., Kramp, W., Shively, R., Wentworth, D.E., Weidemaier, K., Jacobson, R., Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay. iART. Euro Surveill., 22, 2017.
8. Haffizula, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginnochio, C., Bardin, M., Rossignol, J.F., Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomized, placebo controlled, phase 2b/3 trial. Lancet Infect. Dis. 14 (2014), 609–618.
9. Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., Mitamura, K., Kawaoka, Y., Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Jama 297 (2007), 1435–1442.
10. Hayden, F., Influenza polymerase inhibitors. 2nd International Meeting on Respiratory Pathogens, Singapore, 2018.
11. Hurt, A.C., Holien, J.K., Barr, I.G., In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53 (2009), 4433–4440.
12. Hurt, A.C., Besselaar, T.G., Daniels, R.S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R.T., Lo, J., Maurer-Stroh, S., Nguyen, H.T., Pereyaslov, D., Rebelo-de-Andrade, H., Siqueira, M.M., Takashita, E., Tashiro, M., Tilmanis, D., Wang, D., Zhang, W., Meijer, A., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. Antivir. Res. 132 (2016), 178–185.
13. Hurt, A., Komadina, N., Deng, Y.M., Kaye, M., Sullivan, S., Subbarao, K., Barr, I., Detection of adamantane-sensitive influenza A(H3N2) viruses in Australia, 2017: a cause for hope?. Euro Surveill., 22, 2017.
14. Ison, M.G., Antiviral treatments. Clin. Chest Med. 38 (2017), 139–153.
15. Ison, M.G., Gubareva, L.V., Atmar, R.L., Treanor, J., Hayden, F.G., Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193 (2006), 760–764.
16. Lackenby, A., Experimental evolution of resistance to favipiravir in influenza. Oral Presentation at 2nd International Meeting on Respiratory Pathogens, Singapore, 2018.
17. Leang, S.K., Kwok, S., Sullivan, S.G., Maurer-Stroh, S., Kelso, A., Barr, I.G., Hurt, A.C., Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir. Viruses 8 (2014), 135–139.
18. Lin, Y.P., Gregory, V., Collins, P., Kloess, J., Wharton, S., Cattle, N., Lackenby, A., Daniels, R., Hay, A., Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?. J. Virol. 84 (2010), 6769–6781.
19. Meijer, A., Rebelo-de-Andrade, H., Correia, V., Besselaar, T., Drager-Dayal, R., Fry, A., Gregory, V., Gubareva, L., Kageyama, T., Lackenby, A., Lo, J., Odagiri, T., Pereyaslov, D., Siqueira, M.M., Takashita, E., Tashiro, M., Wang, D., Wong, S., Zhang, W., Daniels, R.S., Hurt, A.C., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antivir. Res. 110 (2014), 31–41.
20. Mishin, V.P., Hayden, F.G., Gubareva, L.V., Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49 (2005), 4515–4520.
21. Monto, A.S., McKimm-Breschkin, J.L., Macken, C., Hampson, A.W., Hay, A., Klimov, A., Tashiro, M., Webster, R.G., Aymard, M., Hayden, F.G., Zambon, M., Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 Years of their use 10.1128/AAC.01339-05. Antimicrob. Agents Chemother. 50 (2006), 2395–2402.
22. Naesens, L., Stevaert, A., Vanderlinden, E., Antiviral therapies on the horizon for influenza. Curr. Opin. Pharmacol. 30 (2016), 106–115.
23. Okomo-Adhiambo, M., Nguyen, H.T., Abd Elal, A., Sleeman, K., Fry, A.M., Gubareva, L.V., Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria. Influenza Other Respir. Viruses 8 (2014), 258–265.
24. Pizzorno, A., Bouhy, X., Abed, Y., Boivin, G., Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203 (2010), 25–31.
25. Rana, P., Experimental drug promises to kill the flu virus in a day. Wall St. J., 2018.
26. Rossignol, J.F., Nitazoxanide: a first in class indirect antiviral agent in the treatment of viral respiratory infections caused by orthomyxoviridae and paramyxoviridae. Oral Presentation at the 5th International Society for Influenza and Other Respiratory Viruses (ISIRV-AVG) Conference Shanghai, China June 14-16, 2017, 2018, 118–142 Abstract # S10-7, p 58 in Antiviral Research 2018; 149.
27. Rossignol, J.F., Van Baalen, C., Nitazoxanide: the first broad-spectrum antiviral agent: mechanism of action. Poster Presentation at the 2nd International Meeting on Respiratory Pathogens March 7-9, 2018, 19 Abstract ARP057.
28. Rossignol, J.F., La Frazia, S., Chiappa, L., Ciucci, A., Santoro, M.G., Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284 (2009), 29798–29808.
29. Samson, M., Abed, Y., Desrochers, F.M., Hamilton, S., Luttick, A., Tucker, S.P., Pryor, M.J., Boivin, G., Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. Antimicrob. Agents Chemother. 58:9 (2014), 5220–5228.
30. Sheu, T.G., Deyde, V.M., Okomo-Adhiambo, M., Garten, R., Xu, X., Bright, R., Butler, E., Wallis, T.R., Klimov, A.I., Gubareva, L.V., Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide in 2004-2008. Antimicrob. Agents Chemother. 52:9 (2008 Sep), 3284–3292.
31. Sugaya, N., Cap-dependent endonuclease inhibitor baloxavir marboxil for the treatment of influenza: results from a phase 3, openlabel Study in otherwise healthy pediatric patients with seasonal influenza. 2nd International Meeting on Respiratory Pathogens, Singapore, 2018.
32. Takashita, E., Meijer, A., Lackenby, A., Gubareva, L., Rebelo-de-Andrade, H., Besselaar, T., Fry, A., Gregory, V., Leang, S.K., Huang, W., Lo, J., Pereyaslov, D., Siqueira, M.M., Wang, D., Mak, G.C., Zhang, W., Daniels, R.S., Hurt, A.C., Tashiro, M., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antivir. Res. 117 (2015), 27–38.
33. Tilmanis, D., van Baalen, C., Oh, D.Y., Mifsud, E., Rossignol, J.F., Hurt, A.C., The susceptibility of circulating influenza viruses to Nitazoxanide and the likelihood of resistance. Poster Presentation at the 2nd International Meeting on Respiratory Pathogens March 7-9, 2018, 2018.
34. Trevejo, J.M., Asmal, M., Vingerhoets, J., Polo, R., Robertson, S., Jiang, Y., Kieffer, T.L., Leopold, L., Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir. Ther., 15, 2017 Dec, 10.3851/IMP3212 [Epub ahead of print].
35. WHO, Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec. 87 (2012), 369–374.
36. Yen, H.-L., Hoffmann, E., Taylor, G., Scholtissek, C., Monto, A.S., Webster, R.G., Govorkova, E.A., Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 80 (2006), 8787–8795.
37. Zambon, M., Hayden, F.G., Position statement: global neuraminidase inhibitor susceptibility network. Antivir. Res. 49 (2001), 147–156.